ZLABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Zai Lab Ltd
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$24.06+0.87 (+3.75%)
Close on Oct 19, 2026
- Market cap
- $26.87B
- P/E (TTM)
- –
- Dividend yield
- –
Zai Lab Ltd revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZEJULA | $32.08M | $29.97M | $56.04M | $42.43M | $41.04M | $49.53M | $48.36M | $48.23M | $45.00M | $45.50M | $41.61M | $41.59M | 30.2% | -21.8% |
| VYVGART / VYVGART Hytrulo | $23.87M | $17.55M | $21.87M | $27.73M | $26.50M | $18.11M | $30.02M | $27.27M | $23.19M | – | – | – | 22.4% | -9.9% |
| NUZYRA | $17.10M | $16.26M | $16.00M | $15.43M | $14.29M | $15.12M | $10.99M | $10.00M | $12.30M | $9.91M | $6.07M | $5.48M | 16.1% | +19.6% |
| OPTUNE | $12.20M | $12.07M | $11.95M | $12.66M | $12.36M | $11.36M | $7.70M | $7.72M | $12.58M | $12.48M | $8.37M | $11.56M | 11.5% | -1.2% |
| QINLOCK | $9.59M | $8.99M | $9.67M | $8.90M | $8.54M | $8.51M | $7.05M | $8.64M | $7.04M | $6.09M | $4.71M | $5.70M | 9.0% | +12.3% |
| XACDURO | $7.96M | $8.57M | $10.73M | $6.45M | $4.62M | $1.12M | $3.31M | $0 | $0 | $0 | – | – | 7.5% | +72.2% |
| AUGTYRO | $2.21M | $1.79M | $836.00K | $1.68M | $1.40M | $1.63M | $1.09M | $0 | $0 | $0 | – | – | 2.1% | +58.2% |
| Kar XT | $552.00K | – | – | – | $0 | – | – | – | – | – | – | – | 0.5% | – |
| Other | $195.00K | $357.00K | $0 | $92.00K | $342.00K | $283.00K | $0 | $0 | $0 | $0 | – | – | 0.2% | -43.0% |
| VYVGART / VYVGART Hytrulo | – | – | – | – | – | $18.11M | – | $27.27M | $23.19M | $13.16M | $5.07M | $4.89M | – | – |
By region
From the segment and revenue-disaggregation notes of Zai Lab's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.